MISSISSAUGA, Ontario, June 1, 2005 (PRIMEZONE) -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com), a leading penny stock / small-cap information site, released its latest spotlight company Chemokine Therapeutics Corp. (TSX:CTI).
Chemokine Therapeutics Corp. is a biotechnology company developing drugs in the field of chemokines and cytokines, a family of small, soluble proteins, which signal stem cell transport and growth into mature cells. These stem cells are master primitive cells, capable of producing billions of mature cells necessary for repair and regeneration. The Company's main focus is to develop synthetic versions of chemokines which may have potential applications to address unmet medical needs in cancer, immune deficiencies, vascular disease, and infectious diseases.
Tackling those diseases that still ail the population is where Chemokine Therapeutics is aiming its efforts. A Delaware-based corporation with offices in Vancouver and Manhattan. Chemokine is busy developing peptide-based drugs to treat cancer, cardiovascular and infectious disease, efforts which bore fruit this month with encouraging results from tests of its immune booster compound on healthy volunteers.
A complete CTI profile can be viewed at: http://www.allpennystocks.com/apsc/can/stock_profiles/cti.htm
About AllPennyStocks.com Media Inc.:
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and U.S. site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs weekly penny stocks to watch, has a weekly market write-up, provides company spotlights, runs a unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, Nasdaq and OTC BB, and much more information for the average investor.
Although the majority of AllPennyStocks.com reports are independent, it has received compensation for carrying the report on Chemokine Therapeutics Corp. (TSX:CTI); the amount is seven thousand seven hundred dollars from Chemokine Therapeutics Corp. This creates an inherent conflict of interest and readers are encouraged to view the full disclaimer at http://www.allpennystocks.com/apsc/can/stock_profiles/cti.htm.